

Sonoma Pharmaceuticals, Inc. (SNOA)

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001367083

Sonoma Pharmaceuticals, Inc. SNOA; healthcare	
Grade	E  weakest fifth of 371 graded peers percentile 85.7; sampling error 2.5 points; lower is stronger
Rank	318 of 371
Profitability	C  percentile 51.5
Solvency	D  percentile 75.0
Growth and financing	D  percentile 64.2
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$14.0M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	dilution; fortress balance sheet not computable: distress
Inputs computable	8 of 14
Graded from	filings received through Jun 16, 2026 115 days before the rescans; latest periodic filing 10-Q received Aug 6, 2026
Last close	\$1.17 2026-10-08; market equity \$5.6M
Price used in grade	None

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Jun 16, 2026

Inc. in 1999 under the laws of the State of California. We changed our name to Oculus Innovative Sciences, Inc. in 2001. In December 2006 we reincorporated under the laws of the State of Delaware, and in December 2016 we changed our name to Sonoma Pharmaceuticals, Inc. Conestoga Court, Suite 150, Boulder, Colorado 80301. We have two active wholly-owned subsidiaries: Oculus Technologies of Mexico, S.A. de C.V., and Sonoma Pharmaceuticals Netherlands, B.V. Our fiscal year end is March 31. Our

corporate telephone number is (800) 759-9305. Our websites are www.sonomapharma.com and www.sonomapharma.eu.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 51.5						
Gross profitability		53.1%	32.2%	20.2	372	2026-03-31
Return on invested capital		not computable	9.3%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Accruals ratio		5.5%	(6.6%)	88.8	811	2026-03-31
Gross margin stability, five years		2.6 pts	2.8 pts	45.5	243	2026-03-31
Solvency, sleeve percentile 75.0						
Twelve-month failure probability		not computable	0.07%			four consecutive discrete net-income quarters are required; found 4
Altman Z double-prime		(44.40)	(0.31)	87.2	756	2026-03-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000 interest expense must exceed \$100,000
Interest coverage		not computable	(4.51x)			
Current ratio		2.50x	2.96x	62.8	839	2026-03-31
Growth and financing, sleeve percentile 64.2						
Revenue growth, three-year compound		13.7%	10.0%	41.5	415	2026-03-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		(4.9%)	2.1%	62.2	704	2026-03-31
Net share issuance, one year		191.3%	2.5%	88.8	634	2026-06-15


Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 191.3%
Fortress balance sheet	cash minus debt is 3,355,000 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
313	Amarin Corp. Plc\Uk (AMRN)	84.3	E	fortress balance sheet
314	Kalaris Therapeutics, Inc. (KLRS)	84.6	E	dilution
315	Journey Medical Corp. (DERM)	84.9	E	
316	Amgen Inc. (AMGN)	85.1	E	
317	Organon & Co. (OGN)	85.4	E	
318	Sonoma Pharmaceuticals, Inc. (SNOA) <	85.7	E	dilution, fortress balance sheet
319	Outset Medical, Inc. (OM)	85.9	E	dilution
320	National Vision Holdings, Inc. (EYE)	86.2	E	
321	Natural Alternatives International Inc. (NAII)	86.5	E	dilution, late filer, fortress balance sheet
322	DarioHealth Corp. (DRIO)	86.8	E	dilution, short runway
323	Intellia Therapeutics, Inc. (NTLA)	87.0	E	short runway

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(66.8%)	8.0%	7
Distance from 52-week high	(73.5%)	(31.4%)	11
EBIT to enterprise value	(447.0%)	(1.5%)	2
Free cash flow yield	(74.3%)	(1.0%)	7
Book value to price	1.19	0.28	90
Sales to price	3.52	0.31	96
Composite equity issuance, five years	382.4%	20.3%	97
Relative strength against the sector, log excess return	(1.31)	(0.14)	7

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-03-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	

Cash and equivalents	\$5.3M
Operating cash flow, four quarters	-\$2.6M
Months of runway	25.0
Days since last periodic filing	64 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	\$62,419

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$7.4M	2026-03-31	2026-06-16	10-K	0001683168-26-004871
2	assets	us-gaap:Assets	\$14.0M	2026-03-31	2026-06-16	10-K	0001683168-26-004871
3	operating income	us-gaap:OperatingIncomeLoss	-\$11.3M	2019-03-31	2020-07-10	10-K	0001683168-20-002234
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$11.3M	2019-03-31	2020-07-10	10-K	0001683168-20-002234
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$458,000	2019-03-31	2020-07-10	10-K	0001683168-20-002234
6	total debt	us-gaap:LongTermDebt	\$334,000	2019-03-31	2019-07-01	10-K	0001683168-19-002069
7	book equity	us-gaap:StockholdersEquity	\$7.8M	2019-03-31	2021-07-14	10-K	0001683168-21-002977
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$3.7M	2019-03-31	2021-07-14	10-K	0001683168-21-002977
9	total debt	us-gaap:LongTermDebt	\$262,000	2018-03-31	2018-06-26	10-K	0001683168-18-001786
10	book equity	us-gaap:StockholdersEquity	\$15.3M	2018-03-31	2020-07-10	10-K	0001683168-20-002234
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$10.1M	2018-03-31	2020-07-10	10-K	0001683168-20-002234
12	net income	us-gaap:NetIncomeLoss	-\$3.2M	2026-03-31	2026-06-16	10-K	0001683168-26-004871
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$3.9M	2026-03-31	2026-06-16	10-K	0001683168-26-004871
14	assets	us-gaap:Assets	\$13.7M	2025-03-31	2026-06-16	10-K	0001683168-26-004871
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$19.5M	2026-03-31	2026-06-16	10-K	0001683168-26-004871
16	gross profit	us-gaap:GrossProfit	\$5.5M	2025-03-31	2026-06-16	10-K	0001683168-26-004871
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$14.3M	2025-03-31	2026-06-16	10-K	0001683168-26-004871
18	gross profit	us-gaap:GrossProfit	\$4.7M	2024-03-31	2025-06-17	10-K	0001683168-25-004546
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$12.7M	2024-03-31	2025-06-17	10-K	0001683168-25-004546
20	gross profit	us-gaap:GrossProfit	\$4.5M	2023-03-31	2024-06-17	10-K	0001683168-24-004275
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$13.3M	2023-03-31	2024-06-17	10-K	0001683168-24-004275
22	gross profit	us-gaap:GrossProfit	\$4.0M	2022-03-31	2023-06-21	10-K	0001683168-23-004323
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$12.6M	2022-03-31	2023-06-21	10-K	0001683168-23-004323
24	current assets	us-gaap:AssetsCurrent	\$12.1M	2026-03-31	2026-06-16	10-K	0001683168-26-004871
25	current liabilities	us-gaap:LiabilitiesCurrent	\$4.8M	2026-03-31	2026-06-16	10-K	0001683168-26-004871
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$201.0M	2026-03-31	2026-06-16	10-K	0001683168-26-004871
27	operating income	us-gaap:OperatingIncomeLoss	-\$2.5M	2026-03-31	2026-06-16	10-K	0001683168-26-004871
28	book equity	us-gaap:StockholdersEquity	\$3.1M	2026-03-31	2026-06-16	10-K	0001683168-26-004871
29	liabilities	us-gaap:Liabilities	\$10.9M	2026-03-31	2026-06-16	10-K	0001683168-26-004871
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$453,000	2019-03-31	2020-07-10	10-K	0001683168-20-002234
31	operating income	us-gaap:OperatingIncomeLoss	-\$3.4M	2021-03-31	2022-07-13	10-K	0001683168-22-004940
32	interest expense	us-gaap:InterestExpense	\$12,000	2021-03-31	2021-07-14	10-K	0001683168-21-002977
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$192,000	2026-03-31	2026-06-16	10-K	0001683168-26-004871
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$88,000	2025-03-31	2026-06-16	10-K	0001683168-26-004871
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$80,000	2025-03-31	2026-06-16	10-K	0001683168-26-004871
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$2.4M	2024-03-31	2025-06-17	10-K	0001683168-25-004546
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$2,000	2024-03-31	2025-06-17	10-K	0001683168-25-004546
38	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$6.2M	2023-03-31	2024-06-17	10-K	0001683168-24-004275
39	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$269,000	2023-03-31	2024-06-17	10-K	0001683168-24-004275
40	depreciation amortization	us-gaap:Depreciation	\$139,000	2026-03-31	2026-06-16	10-K	0001683168-26-004871
41	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	-\$3.4M	2026-03-31	2026-06-16	10-K	0001683168-26-004871
42	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$244,000	2026-03-31	2026-06-16	10-K	0001683168-26-004871
43	current assets	us-gaap:AssetsCurrent	\$12.6M	2025-03-31	2026-06-16	10-K	0001683168-26-004871
44	current liabilities	us-gaap:LiabilitiesCurrent	\$4.1M	2025-03-31	2026-06-16	10-K	0001683168-26-004871
45	assets	us-gaap:Assets	\$14.7M	2024-03-31	2025-06-17	10-K	0001683168-25-004546
46	assets	us-gaap:Assets	\$16.2M	2023-03-31	2024-06-17	10-K	0001683168-24-004275
47	shares outstanding	dei:EntityCommonStockSharesOutstanding	4,785,801	2026-06-15	2026-06-16	10-K	0001683168-26-004871
48	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,642,765	2025-06-16	2025-06-17	10-K	0001683168-25-004546